Epidemiological considerations in planning HIV preventive vaccine trials

AIDS

Volumn 15, Issue SUPPL. 5, 2001, Pages

  Esparza, J ^a   Burke, D ^a  

^a WORLD HEALTH ORGANIZATION   (Switzerland)

Author keywords

AIDS; Cohorts; Epidemiology; HIV; Trials; Vaccine

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS VACCINE;

CLINICAL TRIAL; DRUG EFFICACY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOGENICITY; INFECTION PREVENTION; MEDICAL ETHICS; NONHUMAN; PRIORITY JOURNAL; PUBLIC HEALTH; REVIEW; TREATMENT PLANNING; UNITED STATES; VACCINATION; VIRUS GENOME;

EID: 0035668398     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200100005-00008     Document Type: Review

References (103)

1. Accelerating the development and future availability of HIV-1 vaccines: Why, when, where, and how?
2. Current issues in HIV vaccine development
3. Biological considerations in the development of a human immunodeficiency virus vaccine
4. Planning for HIV vaccine trials: The World Health Organization perspective
5. Preparing for HIV vaccine efficacy trials in developing countries
6. Advancing AIDSVAX to phase 3. Safety, immunogenicity, and plans for phase 3
7. Ethical considerations in HIV preventive vaccine research
8. AIDSVAX (MN) in Bangkok injecting drug users: A report on safety and immunogenicity, including macrophage-tropic virus neutralization
9. A phase I/II trial of HIV SF2 gp120/MF59 vaccine in seronegative Thais
10. A phase II study of two type 1 envelope vaccines, comparing their immunogenicity in populations at risk for acquiring HIV type 1 infection
11. HIV vaccine development: A subtype E-specific strategy
12. Development of bivalent (B/E) vaccines able to neutralize CCR5-dependent viruses from the United States and Thailand
13. A comparison of full-length glycoprotein 120 from incident HIV type 1 subtype E and B infections in Bangkok injecting drug users with prototype E and B strains that are components of a candidate vaccine
14. Genetic characterization of incident HIV type 1 subtype E and B strains from a prospective cohort of injecting drug users in Bangkok, Thailand
15. The multi-epitope polypeptide approach in HIV-1 vaccine development
16. A prime-boost regime that combines montanide ISA720 and alhydrogel to induce antibodies against the HIV-1 derived multiepitope polypeptide TAB9
17. HIV-specific cytotoxic T lymphocyte (CTL) response in seronegative Ugandan volunteers vaccinated with HIV-ALYAC CP205: Results of the phase I HIVNET 007 vaccine study
18. Molecular epidemiology of HIV type 1 in a rural community in Southwest Uganda
19. Cellular immunity to human immunodeficiency virus type 1 (HIV-1) clades: Relevance to HIV-1 vaccine trials
20. Identification of highly conserved and bradly cross-reactive HIV type 1 cytotoxic T lymphocyte epitopes as candidate immunogens for inclusion in Mycobacterium bovis BCG-vectored HIV vaccines
21. Design and construction of an experimental HIV-1 vaccine for a year-2000 clinical trial in Kenya
22. Human immunodeficiency virus vaccine development in developing countries: Are efficacy trials feasible?
23. HIV-1 vaccine testing, trial design, and ethics
24. Preparation for phase III HIV vaccine efficacy trials: Methods for the determination of HIV incidence
25. Evaluation of a sensitive/less-sensitive testing algorithm using the 3A11-LS assay for detecting recent HIV seroconversion among individuals with HIV-1 subtype B or E infection in Thailand
26. Establishment of WHO-sponsored field sites for HIV vaccine evaluation in developing countries
27. Design, implementation and evaluation at entry of a prospective cohort study of homosexual and bisexual HIV-1 negative men in Belo Horizonte, Brazil: Project Horizonte
28. Incident HIV infection in a high-risk, homosexual, male cohort in Rio de Janeiro, Brazil
29. Acute retrovirus syndrome among prospectively identified homosexual men with incident HIV infection in Brazil
30. Identification of a high-risk heterosexual population for HIV prevention trials in Rio de Janeiro, Brazil
31. Infection with HIV-1 subtypes B and E in injecting drug users screened for enrolment into a prospective cohort in Bangkok, Thailand
32. Continued high HIV-1 incidence in a vaccine trial preparatory cohort of injection drug users in Bangkok, Thailand
33. Feasibility of a preventive HIV-1 vaccine cohort among persons attending sexually transmitted disease clinics in Thailand
34. Community-based HIV vaccine trial preparation in northern Thailand, 1998-1999: A health fair enrolment approach
35. Trends in HIV-1 incidence in a cohort of prostitutes in Kenya: Implications for HIV-1 vaccine efficacy trials
36. Rapid decline in risk of HIV-1 acquisition after enrolment in a vaccine preparedness cohort of Kenyan prostitutes: Implications for the design of HIV-1 vaccine efficacy trials
37. Trend in HIV-1 prevalence in an antenatal clinic in north Uganda and adjusted rates for the general female population
38. The prevalence and incidence of HIV-1 infection and syphilis in a cohort of police officers in Dar es Salaam, Tanzania: A potential population for HIV vaccine trials
39. High HIV incidence and prevalence among young women in rural South Africa: Developing a cohort for intervention trials
40. Preparing for phase III HIV vaccine trials: Experiences from rural South Africa
41. Factors associated with HIV-1 infection among sex workers of Addis Ababa, Ethiopia
42. HIV/AIDS HIV-1 subtypes: Implications for epidemiology, pathogenesis, vaccines and diagnostics. Workshop Report
43. Approaches to the development of broadly protective HIV vaccines: Challenges posed by the genetic, biological and antigenic variability of HIV-1 (Report from a meeting of the WHO-UNAIDS Vaccine Advisory Committee, Geneva, 21-23 February 2000)
44. An algorithm for evaluating human cytotoxic T lymphocyte responses to candidate AIDS vaccines
45. Broadly cross-reactive HIV-specific cytotoxic T-lymphocytes in highly-exposed persistently seronegative donors
46. A human immunodeficiency virus prime-boost immunization regime in human induces antibodies that show interclade cross-reactivity and neutralize several X4, R5, and dualtropic clade B and C primary isolates
47. The World Health Organization network for HIV isolation and characterization: Summary of a pilot study
48. Understanding the genetic diversity of HIV-1
49. HIV-1 nomenclature proposal
50. Emerging genetic diversity of HIV-1 in South America
51. Evidence of a high frequency of HIV-1 subtype F infections in a heterosexual population in Buenos Aires, Argentina
52. Widespread circulation of a B/F intersubtype recombinant form among HIV-1-infected individuals in Buenos Aires, Argentina
53. HIV-1 diversity in Brazil: Genetic, and immunologic characterization of HIV-1 strains in three potential HIV vaccine evaluation sites. Brazilian network for HIV isolation and characterization
54. HIV disease progression and V3 serotypes in Brazil: Is B different from B-Br?
55. Dual and recombinant infections: An integral part of the HIV-1 epidemic in Brazil
56. Diversity of envelope glycoprotein from human immunodeficiency virus type 1 of recent seroconverters in Thailand
57. A predominant HIV type 1 subtype C-restricted epidemic in South African urban populations
58. Restriction fragment length polymorphism analysis for rapid gag subtype determination of human immunodeficiency virus type 1 in South Africa
59. Phenotypic characteristics of human immunodeficiency virus type 1 subtype C isolates of Ethiopian AIDS patients
60. Identification of a genetic subcluster of HIV type 1 subtype C (C′) widespread in Ethiopia
61. Predominance of HIV-1 subtype A and D infections in Uganda
62. Molecular epidemiology of HIV type 1 in a rural community in Southwest Uganda
63. Genetic analysis of human immunodeficiency virus type 1 strains in Kenya: A comparison using phylogenetic analysis and a combinatorial melting assay
64. V3 sequence analysis and biological characterization of HIV-1 isolates from asymptomatic Tanzanian individuals
65. Most env and gag subtype A HIV-1 viruses circulating in west and west central Africa are similar to the prototype AG recombinant virus IBNG
66. Study of HIV type gag/env variability in The Gambia, using a multiplex DNA polymerase chain reaction
67. Distribution of HIV-1 subtypes among HIV-seropositive patients in the inerior of Cote d'loire
68. Genetic characterization and phylogenetic analysis of HIV-1 subtype C from Uganda
69. Presence of diverse human immunodeficiency virus type 1 viral variants in Cameroon
70. HIV-1 genetic variability in Cameroon
71. Unprecedented degree of human immunodeficiency virus type 1 (HIV-) group M genetic diversity in the Democratic Republic of Congo suggests that the HIV-1 pandemic originate in central Africa
72. Improving comprehension and recall of information for an HIV vaccine trial among women at risk for HIV: Reading level simplification and inclusion of pictures to illustrate key concepts
73. Involving women in HIV vaccine efficacy trials: Lessons learned from a vaccine preparedness study in New York City
74. Feasibility and suitability of targeting young gay men for HIV vaccine efficacy trials
75. Factors related to the willingness of young gay men to participate in preventive HIV vaccine trials
76. Readiness for HIV vaccine trials: Changes in willingness and knowledge among high-risk populations in the HIV network for prevention trials
77. Belief of vaccine receipt in HIV vaccine trials: Further cautions
78. Undergraduates' perception of HIV immunization: Attitudes and behaviours as determining factors
79. Randomized controlled trials of audio computer-assisted self-interviewing: Utility and acceptability in longitudinal studies
80. Evaluation of behavioural and social issues among Thai HIV vaccine trial volunteers
81. Willingness of injection drug users to participate in an HIV vaccine efficacy trial in Bangkok, Thailand
82. Willingness to participate in HIV vaccine trials among men who have sex with men in Rio de Janeiro, Brazil
83. Perception of vulnerability to HIV infection in a cohort of homosexual/bisexual men in Rio de Janeiro, Brazil
84. Community knowledge and attitudes on vaccines and HIV vaccines: A community based preparation for HIV vaccine testing, Rakai district, Uganda
85. The highest attainable standard: Ethical issues in AIDS vaccines
86. HIV vaccine research and human rights: Examples from three countries planning efficacy trials
87. Grappling with global concerns in the search for an HIV vaccine
88. Domestic AIDS vaccine trials: Addressing the potential for social harm to the subjects of human experiments
89. HIV vaccine trials in South Africa - Some ethical considerations
90. HIV vaccines trials and the proposed changes of the Declaration of Helsinki: The fallacy of urgency or ethics vs economics
91. Ethical considerations in international HIV vaccine trials: Summary of a consultative process conducted by the Joint United Nations Programme on HIV/AIDS (UNAIDS)
92. A model for a community advisory board (CAB) to an HIV vaccine phase III clinical trial
93. Cross-cultural issues in the implementation of informed consent in HIV vaccine trials in South Africa
94. Addressing media communication issues in preventive HIV vaccine trails
95. Future access to HIV vaccines (Report from a WHO - UNAIDS Consultation, Geneva, 2-3 October 2000)
96. Willingness of young sexually active heterosexual ethnic minority men and women to participate in HIV vaccine trials
97. Successful recruitment and conduct of the first HIV vaccine efficacy trial in North America and Europe
98. Monitoring of social and behavioural harms in the phase III trial of AIDSVAX® B/B
99. Initiation of a phase III efficacy trial of bivalent B/E rgp 120 HIV vaccine (AIDSVAX™ B/E) in Bangkok, Thailand
100. Baseline characteristics of injecting drug users (IDUs) enrolled in a phase III HIV vaccine efficacy trial - Preliminary results from Bangkok, Thailand
101. AIDS vaccine research in Asia: Needs and opportunities. Report from a UNAIDS/WHO/NIID meeting, Tokyo, 28-30 October 1998
102. Is AIDS vaccine research at a turning point?
103. Evaluating new vaccines for developing countries. Efficacy or effectiveness?